Skip to main content

Table 3 Evaluation of the diagnostic efficiency of single and combined tests for NSCLC [%]

From: A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs

Test item

SEN%

SPE%

PPV%

NPV%

AC%

LR + 

Total CTCs

67.3

83.9

86.8

61.9

73.8

4.2

LCTCs

38.8

67.7

65.5

41.2

50.0

1.2

SCTCs

65.3

93.5

94.1

63.0

76.3

10.1

Triploid CTCs

57.1

96.8

96.6

58.8

72.5

17.7

Tetraploid CTCs

51.0

87.1

86.2

52.9

65.0

4.0

Multiploid CTCs

28.6

96.8

93.3

46.2

55.0

8.9

Total CTECs

77.6

77.4

84.4

68.6

77.5

3.4

LCTECs

67.3

67.7

76.7

56.8

67.5

2.1

SCTECs

67.3

77.4

82.5

60.0

71.3

3.0

Triploid CTECs

49.0

90.3

88.9

52.8

65.0

5.1

Tetraploid CTECs

36.7

71.0

66.7

41.5

50.0

1.3

Multiploid CTECs

59.2

74.2

78.4

53.5

65.0

2.3

SCC + CEA + CYFRA 21–1

52.2

75.8

77.4

50.0

61.3

2.17

CT/PET-CT diagnosis

57.1

77.4

80.0

53.3

65.0

2.48

  1. Large CTCs, LCTCs; small CTCs, SCTCs; Large CTECs, LCTECs; small CTECs, SCTECs
  2. SEN Sensitivity; SPE Specificity; PPV Positive predictive value; NPV Negative predictive value; LR+ Positive likelihood ratio; SCC Squamous cell carcinoma antigen; CEA Carcinoma embryonic antigen; CYFRA21-1 Cytokeratin fragment antigen 21–1